Back to top

Image: Bigstock

What Makes Quotient (QTNT) a Strong Sell?

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Quotient Limited , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in QTNT.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from a loss of $2.18 a share a month ago to its current level of a loss of $2.40.

Also, for the current quarter, Quotient has seen 1 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 62 cents a share from a loss of 44 cents over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 31% in the past month.

QUOTIENT LTD Price and Consensus

QUOTIENT LTD Price and Consensus | QUOTIENT LTD Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Instruments industry, you may instead consider a better-ranked stock - Cogentix Medical, Inc. (CGNT - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Cognyte Software Ltd. (CGNT) - free report >>

Published in